Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01415908 · ClinicalTrials.gov registry record · Phase 3

INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine

A Phase 3 study, sponsored by Medtronic Spinal and Biologics.

Terminated
Registry status
Phase 3
Development phase
15
Enrollment target

NCT01415908: Clinical Trial Phase 3 study, sponsored by Medtronic Spinal and Biologics.

NCT01415908 is a Phase 3 study that was terminated before completion, run by Medtronic Spinal and Biologics. The registered enrollment target is 15 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01415908, a Phase 3 study, was terminated before completion, sponsored by Medtronic Spinal and Biologics.

TERMINATED
Registry status
Phase 3
Development phase
15 participants
Enrollment target

Study Summary

This investigation will provide safety and effectiveness information on the use of INFUSE® Bone Graft with the CAPSTONE® Spinal System and CD HORIZON® Spinal System with a Transforaminal Lumbar Interbody Fusion (TLIF) surgical approach at one or two adjacent levels from L2-S1 to treat subjects with advanced degenerative disease of the lumbosacral spine.

Primary Outcome

Rate of overall success is reported as percent of subjects who met all of the following criteria: 1. fusion at all treated levels (e.g., one level for a one level fusion and two levels for a two level fusion); 2. pain/disability (Oswestry Disability Index) success; 3. neurological status success; 4. no serious adverse event classified as "implant associated" or "implant/surgical procedure associated"; 5. no additional surgical procedure classified as a "failure."

Interventions

  • DEVICE INFUSE Bone Graft
  • OTHER Iliac Crest Bone Graft

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2011-07
Est. Completion 2015-01
Phase Phase 3
Medtronic Spinal and Biologics

26 total trials

Why NCT01415908 stopped before completion

NCT01415908 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which INFUSE Bone Graft is the first listed.

NCT01415908 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01415908 about?

NCT01415908 is a clinical study titled "INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine". This investigation will provide safety and effectiveness information on the use of INFUSE® Bone Graft with the CAPSTONE® Spinal System and CD HORIZON® Spinal System with a Transforaminal Lumbar Interbody Fusion (TLIF) surgical approach at one or two adjacent levels from L2-S1 to treat subjects with ...

What is the current status of trial NCT01415908?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2011-07. Estimated completion is 2015-01.

What interventions are being tested in trial NCT01415908?

The interventions under investigation include: INFUSE Bone Graft (DEVICE), Iliac Crest Bone Graft (OTHER).

Who is sponsoring clinical trial NCT01415908?

This trial is sponsored by Medtronic Spinal and Biologics, which has 26 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01415908's enrollment target sits among peer trials

15 1977th of 2000 higher than 18 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01415908, the US trial registry maintained by the National Library of Medicine. NCT01415908 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.